Loading
TGFBR2 (TGF-beta receptor type-2) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Oesophageal cancer, Pancreatic ductal adenocarcinoma and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and thus regulates a plethora of physiological and pathological processes including cell cycle arrest in epithelial and haematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signalling cascade. Location: Cell membrane; Membrane raft; Secreted (UniProt). Locus 3p24.1 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Colorectal cancer | 3-10% | Frameshift of the polyadenine coding microsatellite | cBioPortal: 416 of 7,237, 5.7%, in crc_msk_2026; 47 of 1,134, 4.1%, in crc_msk_2017; 59 of 1,516, 3.9%, in crc_eo_2020; 23 of 224, 10.3%, in coadread_tcga_pub; 19 of 534, 3.6%, in coadread_tcga_pan_can_atlas_2018; 29 of 619, 4.7%, in coadread_dfci_2016. Eight of the first colon cancer cell lines with high microsatellite instability carried TGFBR2 mutations clustered in short repeated sequences, with no surface receptor and little transcript (Markowitz 1995). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"TGFBR2" OR ABSTRACT:"TGFBR2" OR TITLE:"transforming growth factor beta receptor 2" OR ABSTRACT:"transforming growth factor beta receptor 2" OR TITLE:"TGF-beta receptor type-2" OR ABSTRACT:"TGF-beta receptor type-2" OR TITLE:"TBRII" OR ABSTRACT:"TBRII" OR TITLE:"TBR-ii" OR ABSTRACT:"TBR-ii" OR TITLE:"MFS2" OR ABSTRACT:"MFS2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TGFBR2, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/tgfbr2.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tgfbr2.json. Licence CC BY-NC 4.0.